Loading…
Prothena Corporation plc is projected to rise to $9.17 by 2027, a +13% move from its current price of $8.12. PRTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.95 | $8.12 | $8.30 | +0.05% |
| Aug 4 | $7.88 | $8.13 | $8.38 | +0.10% |
| Aug 5 | $7.83 | $8.13 | $8.44 | +0.15% |
| Aug 6 | $7.79 | $8.14 | $8.50 | +0.20% |
| Aug 7 | $7.75 | $8.14 | $8.55 | +0.25% |
| Aug 8 | $7.72 | $8.14 | $8.59 | +0.29% |
| Aug 9 | $7.69 | $8.15 | $8.63 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.69 | $8.15 | $8.63 | +0.34% |
| Week 2 | $7.54 | $8.18 | $8.87 | +0.69% |
| Week 3 | $7.42 | $8.20 | $9.07 | +1.03% |
| Week 4 | $7.34 | $8.23 | $9.24 | +1.38% |
| Week 5 | $7.26 | $8.26 | $9.40 | +1.73% |
| Week 6 | $7.20 | $8.29 | $9.55 | +2.08% |
| Week 7 | $7.14 | $8.32 | $9.69 | +2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd.
and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc (PRTA) is a healthcare company currently priced at $8.43 with a market cap of $441.34M and a rank of 3153. The stock sits in the healthcare sector with a focus on antibody-based therapies and neurodegenerative disease programs. The current price reflects near-term dynamics, while long-range forecasts outline a substantial upside potential over the coming years.
The forecast indicates a bullish long-term path, with average prices rising from $8.43 in 2026 toward higher levels by 2050 and a multi-fold increase in value, though the near term remains constrained by volatility and macro factors.
A major floor 15.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 23.4% above — a clean break opens room to run.
A major ceiling 41.7% above — clearing it would confirm fresh momentum.
Key PRTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.47 | Sell | $8.40 | Sell |
| MA 10 | $8.55 | Sell | $8.54 | Sell |
| MA 20 | $8.82 | Sell | $8.73 | Sell |
| MA 50 | $9.05 | Sell | $9.07 | Sell |
| MA 100 | $9.54 | Sell | $9.30 | Sell |
| MA 200 | $9.64 | Sell | $9.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.14 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -122.71 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -3.68 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -0.50 | Sell |
| Ultimate (7,14,28) | 33.79 | Neutral |
| Momentum (10) | -0.54 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 8.35 | Sell |
| ADX (14) | 16.79 | Neutral |
| ATR (14) | 0.18 | Info |
In the next 30 days, the technical picture is bearish with an RSI of 40. The price trades below the SMA50 of $9.43 and the SMA200 of $9.72, signaling continued near-term pressure. The stock’s near-term levels show support at $7.91 and resistance at $10.02, with a 30-day price range of $7.07 to $10.05.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.91 | $8.12 | $10.85 | 0% | Neutral | |
| $7.45 | $9.17 | $11.85 | +13% | Neutral | |
| $7.97 | $10.03 | $13.37 | +24% | Bullish | |
| $7.82 | $10.02 | $13.69 | +23% | Bullish | |
| $8.16 | $10.62 | $14.80 | +31% | Bullish | |
| $8.83 | $11.67 | $16.55 | +44% | Bullish | |
| $9.40 | $12.59 | $18.15 | +55% | Bullish | |
| $11.01 | $14.93 | $21.84 | +84% | Bullish | |
| $11.76 | $16.14 | $23.92 | +99% | Bullish | |
| $11.47 | $15.91 | $23.88 | +96% | Bullish | |
| $15.91 | $23.21 | $36.72 | +186% | Bullish | |
| $25.21 | $40.04 | $68.43 | +393% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.91 | $8.12 | $9.79 | +0.00% |
| September 2026 | $6.98 | $8.21 | $9.89 | +1.07% |
| October 2026 | $7.18 | $8.49 | $10.32 | +3.47% |
| November 2026 | $7.41 | $8.80 | $10.78 | +3.68% |
| December 2026 | $7.38 | $8.80 | $10.85 | +0.01% |
Click any year to see its month-by-month PRTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Prothena Corporation plc's 2026 outlook centres on $8.12, within a $7.91 to $10.85 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PRTA could reach as high as $11.85, with a base case around $9.17 and support toward $7.45 — roughly +13% from $8.12. A consolidation phase looks the most probable path here.
Expect PRTA to range from $7.97 to $13.37 through 2028. The $10.03 average target implies a +24% move from current prices. That is up +9% on the projected 2027 average. Momentum favours further upside here.
The PRTA price prediction for 2029 points to an average of $10.02 (low $7.82, high $13.69) — a potential gain of +23% on today's $8.12. Buyers look set to stay in control over this stretch.
In 2030, PRTA is projected to trade between $8.16 and $14.80, averaging $10.62 — a potential gain of +31% from today's $8.12. That is up +6% on the projected 2029 average. Momentum favours further upside here.
Prothena Corporation plc's 2031 outlook centres on $11.67, within a $8.83 to $16.55 range. That is up +10% on the projected 2030 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PRTA could reach as high as $18.15, with a base case around $12.59 and support toward $9.40 — roughly +55% from $8.12. Momentum favours further upside here.
Expect PRTA to range from $11.01 to $21.84 through 2033. The $14.93 average target implies a +84% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PRTA price prediction for 2034 points to an average of $16.14 (low $11.76, high $23.92) — a potential gain of +99% on today's $8.12. Momentum favours further upside here.
In 2035, PRTA is projected to trade between $11.47 and $23.88, averaging $15.91 — a potential gain of +96% from today's $8.12. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Prothena Corporation plc's 2040 outlook centres on $23.21, within a $15.91 to $36.72 range. That is up +46% on the projected 2035 average. That marks a +186% change versus current levels. Momentum favours further upside here.
By 2050, PRTA could reach as high as $68.43, with a base case around $40.04 and support toward $25.21 — roughly +393% from $8.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRTA today (≈ 123.152709 PRTA) could be worth
$4,930.74
+$3,930.74 (+393%) by 2050 · US Dollar
Based on the average projected PRTA price of $40.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRTAwould be worth at today's price.
$1,000 invested in PRTA on Jul 31, 2025 (≈ 145.56041 PRTA) would be worth
$1,181.95
+$181.95 (+18.2%) today · 1.18× · US Dollar
Based on a PRTA entry price of $6.87 vs. today's $8.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.75 | $928 | -7.2% |
| 1 month ago | $9.58 | $847.6 | -15.2% |
| 3 months ago | $10.64 | $763.16 | -23.7% |
| 6 months ago | $8.91 | $911.34 | -8.9% |
| 1 year ago | $6.87 | $1,181.95 | +18.2% |
| All time (5.0y) ago | $54.1 | $150.09 | -85.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRTA forecast.
Our base-case forecast reaches $16.00 around 2034.
Implied market cap at $16.00: $837.65M
The multi-year forecast shows a bullish trajectory after 2026, with the average price rising through successive years and expanding ROI. For 2026 the avg is $8.43 with an ROI of 0% and neutral sentiment. By 2027 the avg is $9.61 (ROI 13.9%) and by 2028 the avg is $10.44 (ROI 23.9%), continuing with 2030 at $10.95 (ROI 29.9%).
The forecast strengthens further in 2031–2035, with 2031 avg $11.93 (ROI 41.6%), 2032 $12.88 (52.8%), 2033 $15.92 (88.8%), 2034 $16.89 (100.4%), and 2035 $16.08 (90.8%), all bullish. The path extends to 2040 with avg $24.15 (ROI 186.4%) and to 2050 with avg $40.75 (ROI 383.4%), remaining bullish across the horizon. These are estimates, not guarantees, and actual results will vary with clinical outcomes, regulatory decisions, and market conditions.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $10.95 with a range from $8.15 to $15.84 and a projected ROI of 29.9%, with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with the 2030–2050 path featuring rising averages (e.g., 2030 avg $10.95; 2050 avg $40.75) and a long-run ROI up to 383.4%. These are estimates and not guarantees.
According to the forecast, the 2050 max is $74.62, which is below $75.
Current price is $8.43 and market cap is $441.34M.
Prasinezumab in Phase 3 for parkinson's disease and other synucleinopathies; Coramitug in Phase 3 for transthyretin amyloidosis; BMS-986446 in Phase 2 for Alzheimer’s disease; PRX019 in Phase 1 for neurodegenerative diseases; PRX123 in preclinical for Alzheimer's disease; additional programs include TDP-43 CYTOPE, PRX012 in Phase 1 for Alzheimer's, and PRX012-TfR preclinical; license with Roche for antibodies targeting alpha-synuclein and a master collaboration with Bristol Myers Squibb for tau and TDP-43.
Prothena Corporation plc Community Discussion
0Share your Prothena Corporation plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.